Allopurinol to prevent liver disease complications
Treatments studied
Part of Digestive system clinical trials.
This study tests if allopurinol, a medicine that lowers uric acid, can help prevent serious complications in people with advanced liver disease. It may reduce the risk of problems like fluid buildup or confusion.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have been diagnosed with decompensated cirrhosis (advanced liver disease with complications).
- Your liver function is moderate to severely impaired (Child-Turcotte-Pugh score B or C).
- You have not had recent episodes of hepatic encephalopathy, spontaneous bacterial peritonitis, or kidney injury related to liver disease in the last 4 weeks.
- You do not have severe kidney problems (creatinine clearance less than 30 mL/min).
- You are not pregnant or breastfeeding, and you are not taking certain medications that interact with allopurinol.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether allopurinol can reduce the chance of cardiovascular events like heart attack, stroke, or related problems in people who are at higher risk. It targets people with higher uric acid and other risk factors, to see if lowering uric acid helps protect the heart.
This study compares two different treatment goals for a blood level called urate in people with gout. The goal is to see which approach lowers gout flares better while helping people feel better.
This trial studies alverine to lower portal hypertension, which is high blood pressure in the liver that can happen with cirrhosis. If it works safely, it may reduce pressure-related complications in people with confirmed liver scarring.
This trial tests whether the blood thinner apixaban can help prevent early-stage cirrhosis from worsening. You may be eligible if you have compensated (stable) cirrhosis due to alcohol and have signs of portal hypertension.
This study tests how a new drug, ABP-671, interacts with allopurinol (a common gout medicine) in people with gout. It is looking for participants with normal or moderately reduced kidney function.
This study tests if sulfasalazine, a medicine already used for other conditions, is safe and helpful for people with liver scarring (fibrosis or cirrhosis). It is for patients with cirrhosis caused by certain liver diseases, like PBC, hepatitis B, hepatitis C, or alcohol use.
Hear when a new Cirrhoses, Liver trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.